header logo image


Page 938«..1020..937938939940..950960..»

Eye doctor explains why you shouldn’t look at the sun during the … – NorthJersey.com

August 19th, 2017 7:41 am

Experts are warning people about counterfeit eclipse glasses.

Watching solar eclipse(Photo: Daniel MacDonald / http://www.dmacphoto.com, Getty Images/Flickr RF)

You've heard over and over that you shouldn't look up at the sun during Monday's solar eclipse (or ever, as a general rule), but what actually happens if you do?

Dr. Jacob Chung, Chief of Opthalmology at Englewood Hospital and Medical Center, answered our burning (ahem) questions about what'll happenif you just can't help but take a peek sans ISO-approved glasses during the big event.

If you look at it for a second or two, nothing will happen. Five seconds, I'm not sure, but 10 seconds is probably too long and 20 seconds is definitely too long.

The eye works like a camera, and the retina is like the film of your eye. So looking at the sun too long is almost like burning a hole in the center of your film, or retina. We don't have pain fibers there so you won't have discomfort or feel pain, but you might see a fuzzed out, dark spot.

The retina can't heal itself, so the blind spot is permanent and cannot be treated, but definitely go see a doctor to make sure it's the right diagnosis.

ECLIPSE GUIDE: Everything you need to know about the solar eclipse

GLASSES: 5 places to get eclipse glasses before the big day

If you're in that 70-mile swath where you'll be able to see the total eclipse [parts of Oregon, Idaho, Wyoming, Nebraska, Montana, Illinois, Kentucky, South Carolina], you have about a two-minute window where the sun is 100 percent eclipsed. Because we have a partial eclipse, there is a zero-second window where it's safe to look at the sun directly.

Look, no one loves to look at the sun: it hurts. The reason it's more dangerous during the eclipse is because you don't feel much discomfort, yet your eyes are receiving all the harm. It's similar to getting sunburnedon a cloudy day.

[Chuckles] Yes.

They filter out a lot more of the sun's harmful radiation something like 100,000 times more than standard sunglasses.

The best alternative is to visualize it from an indirect method. Put your phone camera on selfie mode, then turn your back to the sun and see the eclipse that way.

Or, take twopieces of cardboard or paper. Cut a hole in one and again, turn yourback to the sun and hold it up against the second one. Thesun will cast its rays through the pinhole, [creating a projection on the second piece of cardboard/paper].

I had a case many years ago of a gentleman who had a condition called solar retinopathy. I don't know if it was during an eclipse, but he said he was on LSD and looked at the sun for four straight hours. In hisretina there was a pigmented spot and his vision was very poor, needless to say. Hewas basically legally blind.

In summer, of course, since we're closer to the sun. But there are different ways you can get damage from the sun in your eyes. If you are outdoors a lot you can get a growth on the surface of your eye, called pterygium. It's found very commonly in people who live or grew up in equatorial regions, and a lot of surfers get itbecause the water reflects UV into eyes [the condition is also called Surfer's Eye]. If very severe, it can start to obscure your vision and cause irritation from time to time. That can be surgically removed, however.

Chronic sun exposure can also contribute to formation of cataracts and macular degeneration. So, wear sunglasses as often as it makes sense to.

Read or Share this story: https://njersy.co/2wirE43

The rest is here:
Eye doctor explains why you shouldn't look at the sun during the ... - NorthJersey.com

Read More...

Blood cancer: High doses of vitamin C could encourage stem cells to die – Express.co.uk

August 17th, 2017 8:48 pm

The study suggests it may encourage blood cancer stem cells to die.

Researchers say Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers.

They explained that certain genetic changes are known to reduce the ability of an enzyme called TET2 to encourage stem cells to become mature blood cells, which eventually die, in many patients with certain kinds of leukaemia.

The new study, published online by the journal Cell. found that vitamin C activated TET2 function in mice engineered to be deficient in the enzyme.

Study corresponding author Professor Benjamin Neel, of the Perlmutter Cancer Centre in the United States, said: "We're excited by the prospect that high-dose vitamin C might become a safe treatment for blood diseases caused by TET2-deficient leukemia stem cells, most likely in combination with other targeted therapies."

He said changes in the genetic code that reduce TET2 function are found in 10 per cent of patients with acute myeloid leukaemia (AML), 30 per cent of those with a form of pre-leukaemia called myelodysplastic syndrome, and in nearly 50 per cent of patients with chronic myelomonocytic leukaemia.

Such cancers cause anaemia, infection risk, and bleeding as abnormal stem cells multiply in the bone marrow until they interfere with blood cell production, with the number of cases increasing as the population ages.

Prof Neel said the study results revolve around the relationship between TET2 and cytosine, one of the four nucleic acid "letters" that comprise the DNA code in genes.

To determine the effect of mutations that reduce TET2 function in abnormal stem cells, the researchers genetically engineered mice such that the scientists could switch the TET2 gene on or off.

Similar to the naturally occurring effects of TET2 mutations in mice or humans, using molecular biology techniques to turn off TET2 in mice caused abnormal stem cell behaviour.

Prof Neel said, remarkably, the changes were reversed when TET2 expression was restored by a genetic trick.

Previous work had shown that vitamin C could stimulate the activity of TET2 and its relatives TET1 and TET3.

Because only one of the two copies of the TET2 gene in each stem cell is usually affected in TET2-mutant blood diseases, the researchers hypothesised that high doses of vitamin C, which can only be given intravenously, might reverse the effects of TET2 deficiency by turning up the action of the remaining functional gene.

They found that vitamin C did the same thing as restoring TET2 function genetically.

By promoting DNA demethylation, high-dose vitamin C treatment induced stem cells to mature, and also suppressed the growth of leukaemia cancer stem cells from human patients implanted in mice.

Study first author Doctor Luisa Cimmino, of New York University Langone Health, said: "Interestingly, we also found that vitamin C treatment had an effect on leukaemic stem cells that resembled damage to their DNA.

"For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer."

The researchers found that the combination had an enhanced effect on leukaemia stem cells, further shifting them from self-renewal back toward maturity and cell death.

Dr Cimmino said the results also suggest that vitamin C might drive leukaemic stem cells without TET2 mutations toward death, given that it turns up any TET2 activity normally in place.

Corresponding author Professor Iannis Aifantis, also of NYU Langone Health, added: "Our team is working to systematically identify genetic changes that contribute to risk for leukaemia in significant groups of patients.

"This study adds the targeting of abnormal TET2-driven DNA demethylation to our list of potential new treatment approaches."

Continued here:
Blood cancer: High doses of vitamin C could encourage stem cells to die - Express.co.uk

Read More...

From death’s door to mountain top, beating cancer the Geoff Thomas way – iNews

August 17th, 2017 8:47 pm

Only 3,224 miles to go. Let me at it, says Geoff Thomas as he prepares to set off around Spain, 21 days of pure agony covering every inch of La Vuelta, each stage completed 24 hours before the peloton attacks the third and final grand tour of the season.

Thomas is a cancer survivor dedicated through his own foundation to raising cash and awareness of blood cancer, the disease that struck down the former Crystal Palace midfielder in 2003. Thomas was diagnosed with chronic myeloid leukaemia and given just three months to live. It was, he says, a dark place, yet here he is 12 years in remission and immersed in another lung busting slog to make life possible for others.

The scale of the challenge is insane, or stupid as Thomas describes it, for a bunch of amateur cyclists, one of whom is 67 years old. Having already completed the Giro dItalia and the Tour de France on the same terms this year there is no backing out now.

The initiative is after all called the Geoff Thomas Three Tours Challenge, and for better or worse he will be in the saddle on Friday alongside four equally committed travellers to attempt something only 39 professional riders have done before. The hope is to funnel more than 1m to Cure Leukaemia, the charity set up by the man he credits with saving his life Professor Charlie Craddock.

I got involved in all this through going through the illness. My only chance of survival was stem cell replacement. At my first meeting with a doctor I was given three months to live. The next day I saw Professor Craddock and he put me in intensive chemo straight away. He offered a different prognosis, saying I might have three years.

I was lucky my sister was a very good match as the donor. The treatment more or less kills you then they bring you back to life. My sister had to have the stem cells removed from her spine, quite a painful procedure. These days its like giving blood. They harvest the cells from a blood sample. As a result more people are going on the donors list.

Back when I was diagnosed there was a clinical trial that I couldnt get on. It proved very successful, resulting in survival rates of more than 90 per cent for the drug involved. There was no real infrastructure to run clinical trials back in 2003. A lot of hospitals did not have the facilities, no clinical researchers in place etc. For a small amount of money in the grand scheme we are now able to put that into place.

Hospitals are now working together to get the results required and survival rates have gone up. As a result of the work we have done with clinical trials we have seen almost 200m worth of drugs available for free to patients on the NHS. And that is something we are really proud of.

The fight goes on, and so do the fundraisers, and for this one, you can never be ready, says Thomas. Some of the climbs are ridiculous. I dont look at the course or whats head I just think of bringing enough weight to bear on the pedal to turn the wheel. And you have to be lucky.

I missed a few days of the Tour de France after I fell and injured my hip. It was only on day two, a flat bit, and it became infected about ten days later. I was gutted to have to stop but I realised my aim is to get awareness out there and pull in the money that I know is making a difference to peoples lives. This is the final leg. Im determined tol stay on the bike this time and make it to the end.

View original post here:
From death's door to mountain top, beating cancer the Geoff Thomas way - iNews

Read More...

Cisplatin Combination Kills Rare Cancer Cells in Mice – Bioscience Technology

August 17th, 2017 8:47 pm

An experimental drug combined with the traditional chemotherapy drug cisplatin, when used in mice, destroyed a rare form of salivary gland tumor and prevented a recurrence within 300 days, a University of Michigan study found.

Called adenoid cystic carcinoma, or ACC, this rare cancer affects 3,000-4,000 people annually, and typically arises in the salivary glands. It's usually diagnosed at an advanced stage, is very resistant to therapy, and there's no cure. People may have read about ACC in the news lately, because elite professional runner Gabe Grunewald is currently undergoing her fourth round of treatment since her 2009 ACC diagnosis.

Typically, oncologists treat ACC tumors with surgery and radiation. They rarely use chemotherapy because ACC is extremely slow-growing, and chemotherapy works best on cancers where cells divide rapidly and tumors grow quickly, said Jacques Nr, a U-M professor of dentistry, otolaryngology and biomedical engineering, and principal investigator on the study.

The Nr lab treated ACC tumors with a novel drug called MI-773, and then combined MI-773 with traditional chemotherapy cisplatin. MI-773 prevents a molecular interaction that causes tumor cells to thrive by disarming the critical cancer fighting protein, p53.

Study co-author Shaomeng Wang, U-M professor of medicine, pharmacology and medicinal chemistry, discovered MI-773, which is currently licensed to Sanofi.

Researchers believe that blocking that interaction sensitized ACC cancer cells to cisplatina drug that under normal conditions, wouldn't work. When administered to the mice with ACC tumors, the cisplatin targeted and killed the bulk cells that form the tumor mass, while MI-773 killed the more resistant cancer stem cells that cause tumor recurrence and metastasis.

"This drug MI-773 prevents that interaction, so p53 can induce cell death," Nr said. "In this study, when researchers activated p53 in mice with salivary gland cancer, the cancer stem cells died."

The key is that in many other types of cancer, p53 is mutated so it can't kill cancer cells, and this mutation renders the MI-773 largely ineffective. However, in most ACC tumors p53 is normal, and Nr said researchers believe this makes these tumors good candidates for this combined therapy.

Researchers performed two different types of experiments to test ACC tumor reduction and recurrence. First, they treated tumors in mice with a combination of MI-773 and cisplatin, and tumors shrank from about the size of an acorn to nearly zero.

In the second experiment, the acorn-sized tumors were surgically removed, and for one month the mice were treated with MI-773 only, with the hope of eliminating the cancer stem cells that fuel recurrence and metastasis.

"We did not observe any recurrence in the mice that were treated with this drug after 300 days (about half of mouse life expectancy), and we observed about 62 percent recurrence in the control group that had only the surgery," Nr said. "It's our belief that by combining conventional chemotherapy with MI-773, a drug that kills more cancer stem cells, we can have a more effective surgery or ablation."

One limitation of the study is that it's known that about half of all ACC tumors recur only after about 10 years, and this observational period was only 300 days.

In a typical metastasis, the cancer cells spread through the blood to other parts of the body. But ACC cancer cells like to move by "crawling" along nerves, and it's common for ACC tumor cells to follow the prominent facial nerves to the brainpicture a mountain climber ascending a ropewhere it's often fatal.

Research is still too early-stage to know how humans will respond, and the drug will work primarily in tumors where p53 is normal. If p53 is mutated, which is fairly common in other tumor types, this drug won't work as well, Nr said.

The work was funded by the Adenoid Cystic Carcinoma Research Foundation, U-M and the National Institutes of Health.

The study, "Therapeutic Inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas," appeared earlier this year in the journal Clinical Cancer Research.

See the original post:
Cisplatin Combination Kills Rare Cancer Cells in Mice - Bioscience Technology

Read More...

FDA OKs Pfizer drug for rare, fast-killing type of leukemia – ABC News

August 17th, 2017 8:47 pm

The Food and Drug Administration has approved a new medicine for use against a rare, rapidly progressing blood cancer after other treatments have failed.

The agency approved Pfizer Inc.'s Besponsa for patients with a type of advanced acute lymphoblastic leukemia. By then, life expectancy is low.

"These patients have few treatments available and today's approval provides a new, targeted treatment option," Dr. Richard Pazdur, the FDA's director for cancer drugs, said in a statement.

This year an estimated 5,970 Americans will be diagnosed and 1,440 will die from the cancer, according to the National Cancer Institute.

The drug will cost $168,300 without insurance for the typical nine-week treatment course.

In testing that included 218 patients, 36 percent given Besponsa had their cancer vanish for eight months on average; 17 percent of those given chemotherapy had complete remission for a median five months.

Besponsa is believed to work by blocking the growth of cancerous cells by binding to their surface.

The powerful injected drug, known chemically as inotuzumab ozogamicin, comes with the FDA's most-stringent warning because it can cause severe liver disease, including blocking veins in the liver. It also carries an increased risk of death in patients who have received a certain type of stem cell transplant.

Besponsa also can cause a decrease in blood-cell and platelet production, infusion-related reactions and problems with the heart's electrical pulses. Women who are pregnant or breastfeeding should not take Besponsa because it may harm a developing fetus or a newborn baby, the FDA warned.

More-common side effects include fatigue, severe bleeding, fever, nausea and headaches.

Follow Linda A. Johnson at http://www.twitter.com/LindaJonPharma

Follow this link:
FDA OKs Pfizer drug for rare, fast-killing type of leukemia - ABC News

Read More...

Traffic fumes ‘increase infection risk by damaging immune system’ – Birmingham Mail

August 17th, 2017 8:47 pm

Air pollution could increase the risk of infection by damaging the immune system, according to a study.

Scientists have demonstrated for the first time that nano-sized particles in traffic fumes reduce the body's ability to kill viruses and bacteria.

While the potential link between car-choked streets and illness has been the subject of much debate, the work at Edinburgh Napier University is the first to show this effect and presents significant human health implications.

Dr Peter Barlow, who led the research, said: "This is an area of research that is very poorly understood.

"We were extremely concerned when we found that air pollution particles could inhibit the activity of these molecules, which are absolutely essential in the fight against infection.

"In light of these findings, we urge that strong action plans are put in place to rapidly reduce particulate air pollution in our towns and cities."

The study focused on tiny molecules found in the immune systems of humans and animals, known as antimicrobial peptides, which increase in response to infection.

It found carbon particles could trigger changes in the molecules, potentially resulting in "an increased susceptibility to infection".

The implications are potentially profound for people living in areas of high air pollution, who breathe in huge concentrations of particles every day or absorb them through skin contact.

Those with pre-existing lung conditions like asthma or chronic obstructive pulmonary disease are said to be especially vulnerable.

More here:
Traffic fumes 'increase infection risk by damaging immune system' - Birmingham Mail

Read More...

Scripps Research Institute Awarded $11.2M for Mammalian Immune System Project – Times of San Diego

August 17th, 2017 8:47 pm

Share This Article:

The Scripps Research Institute announced Thursday that it was awarded a five-year, $11.2 million federal grant to continue a long- running project to reveal the detailed workings of the mammalian immune system.

The project, which also includes professors from the Center for Infectious Disease Research in Seattle, Stanford University and the University of Texas Southwestern, aims to map the molecular and cellular interactions that underlie immunity and inflammation in health and disease. That in turn should enable the invention of better drugs and vaccines for infections, inflammatory diseases, and other immune-related ailments, according to TSRI.

The project has been funded by the National Institute for Allergic and Infectious Diseases, part of the National Institutes of Health, for 15 years.

It is one of the most productive large-scale science grants that NIAID funds, said Richard Ulevitch professor in TSRIs Department of Immunology.

The researchers use a system called forward genetics, in which the scientists create random DNA mutations in a population of test animals.

They screen the animals for resulting immune-related changes and, when they find significant ones, use state-of-the-art DNA sequencing technology to identify the mutated genes that caused the modifications.

The researchers also mine existing literature on gene and protein function, and apply the statistical and computational methods of systems biology, to connect the data points and thereby map the networks that underlie immunity.

Over the years, the scientists have published noteworthy findings in scientific journals and maintained online databases with their results.

City News Service

Scripps Research Institute Awarded $11.2M for Mammalian Immune System Project was last modified: August 17th, 2017 by Debbie L. Sklar

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Go here to see the original:
Scripps Research Institute Awarded $11.2M for Mammalian Immune System Project - Times of San Diego

Read More...

A pathology atlas of the human cancer transcriptome – Science Magazine

August 17th, 2017 8:47 pm

Mathias Uhlen

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.Center for Biosustainability, Danish Technical University, Copenhagen, Denmark.School of Biotechnology, AlbaNova University Center, KTHRoyal Institute of Technology, Stockholm, Sweden.

Cheng Zhang

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Sunjae Lee

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Evelina Sjstedt

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Linn Fagerberg

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Gholamreza Bidkhori

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Rui Benfeitas

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Muhammad Arif

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Zhengtao Liu

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Fredrik Edfors

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Kemal Sanli

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Kalle von Feilitzen

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Per Oksvold

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Emma Lundberg

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Sophia Hober

School of Biotechnology, AlbaNova University Center, KTHRoyal Institute of Technology, Stockholm, Sweden.

Peter Nilsson

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Johanna Mattsson

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Jochen M. Schwenk

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.

Hans Brunnstrm

Division of Pathology, Lund University, Skne University Hospital, Lund, Sweden.

Bengt Glimelius

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Tobias Sjblom

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Per-Henrik Edqvist

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Dijana Djureinovic

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Patrick Micke

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Cecilia Lindskog

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Adil Mardinoglu

Science for Life Laboratory, KTHRoyal Institute of Technology, Stockholm, Sweden.School of Biotechnology, AlbaNova University Center, KTHRoyal Institute of Technology, Stockholm, Sweden.Department of Biology and Biological Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden.

Fredrik Ponten

Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.

More:
A pathology atlas of the human cancer transcriptome - Science Magazine

Read More...

Blood Biopsy Reveals Unique, Targetable Genetic Alterations in Patients with Rare Cancer – UC San Diego Health

August 17th, 2017 8:47 pm

Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.

In order to plan treatment for cancer in general, physicians first attempt to pinpoint the primary cancer where the tumor first developed. In CUP, despite its spread throughout the body, the origin remains unknown, making treatment more difficult. The current standard of care is platinum-based combination chemotherapies with a median survival time of six to eight months.

Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center at UC San Diego Health.

In a study published in the journal Cancer Research on August 15, researchers report that by sequencing circulating tumor DNA (ctDNA) derived from blood samples in 442 patients with CUP, they were able to identify at least one genetic alteration linked to cancer in 290 66 percent of patients. Researchers used a screening test developed by Guardant Health that evaluates up to 70 genes. Based on known carcinogenic mutations, 99.7 percent of the 290 patients who had detectable tumor DNA in their bloodstream had genomic alterations that could hypothetically be targeted using existing FDA-approved drugs (as off-label use) or with therapies currently under investigation in clinical trials.

By definition, CUP does not have a definite anatomical diagnosis, but we believe genomics is the diagnosis, said Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center at UC San Diego Health and senior author. Cancer is not simple and CUP makes finding the right therapy even more difficult. There are multiple genes and abnormalities involved in different areas of the body. Our research is the first to show that evaluating circulating tumor DNA from a tube of blood is possible in patients with CUP and that most patients harbor unique and targetable alterations.

A blood or liquid biopsy is a diagnostic tool based on the idea that critical genetic information about the state of disease can be found in blood or other fluids. One vial of blood could be used to detect the onset of disease, monitor its progression and measure its retreat less invasively than a tissue biopsy.

Shumei Kato, MD, assistant professor of medicine at UC San Diego School of Medicine.

Another advantage of the liquid biopsy is that the location of the cancer does not matter, said Shumei Kato, MD, assistant professor of medicine at UC San Diego School of Medicine and first author. With a blood sample, we can analyze the DNA of tumors throughout the body to find targetable alterations. With tissue biopsies, we can only see genomic changes that are in that one site and that may not be the same as what is in different sites not biopsied, such as the lung or bone.

Liquid biopsies are relatively simple to get and can be obtained regularly to monitor changes over time, as was the case with a 60-year-old woman with CUP. Her case, which was evaluated by Brian Leyland-Jones, MB, BS, PhD and study co-author with colleagues at Avera Cancer Institute, was described in the study to show the changes observed in ctDNA over the course of her treatment.

What we saw was that the patient was responding to treatment, but the cancer had emerging new mutations, said Kurzrock. Whats new here is that we can do the same evaluation through a blood test that we previously could only do with a tissue sample. You will see these changes with a simple blood test and it is easy to repeat blood tests, but hard to repeat tissue biopsies.

The study also reported the case of an 82-year-old man who was prescribed a checkpoint inhibitor immunotherapy as part of his treatment because of a mismatch repair gene anomaly that is typically observed in less than two percent of patients. He showed a partial response within eight weeks and blood biopsies showed the tumor DNA disappearing.

We can see that each patient has different mutations in their tumor DNA, which means that treatment plans cannot be a one-size-fits-all approach; a personalized approach is needed, said Kato.

Kurzrock is already using liquid biopsy technology in the Profile Related Evidence Determining Individualized Cancer Therapy (PREDICT) clinical trial a project focusing on the outcome of patients who have genomic testing performed on their tumors and are treated with targeted therapy.

The authors suggest that a liquid biopsy approach should be further investigated in next-generation clinical trials focusing on CUP.

Co-authors include: Nithya Krishnamurthy, Scott M. Lippman, UC San Diego; Kimberly C. Banks, Richard B. Lanman, Guardant Health, Inc.; Pradip De, Kirstin Williams, and Casey Williams, Avera Cancer Institute.

This research was funded, in part, by the National Cancer Institute (P30 CA016672) and the Joan and Irwin Jacobs fund.

Disclosure: Razelle Kurzrock receives consultant fees from X-biotech and from Actuate Therapeutics, as well as research funds from Genentech, Pfizer, Sequenom, Guardant, Foundation Medicine and Merck Serono, and has an ownership interest in Novena Inc. and CureMatch Inc.

Read the original post:
Blood Biopsy Reveals Unique, Targetable Genetic Alterations in Patients with Rare Cancer - UC San Diego Health

Read More...

On the trail of yellow fever – Science Magazine

August 17th, 2017 8:44 pm

Monkeys and mosquitoes hold clues to when and where the virus could resurge in Brazil.

Researchers Bruna Sena Nascimento (foreground) and Hlio Saraiva climb a tree to capture mosquitoes in the canopy in Santa Barbara, Brazil.

The howler monkeys slink like cats through the canopy, swiveling their heads to look for danger. They have reason to be wary. In the jungle below, biologists armed with a black tranquilizer rifle are hunting them, flashes of khaki through the foliage.

The scientists signal each other with snaps and whistles and pivot directions frequently; they often cross trails perpendicularly instead of following them. As they maneuver for clean shots, thick leaves come rattling down through the branches. In the distance, marmosets whistle.

The scientists are on Ilha Grande, an island off southern Brazil that once housed a notorious maximum security prison. Resorts dot the perimeter today, but untouched jungle dominates the interior. Brazil recently experienced its worst outbreak of yellow fever in decades with hundreds of cases, some just east of Ilha Grande. So scientists plan to test local howler monkeys (called bugios) for the virus to learn whether it has spread here, too. If they can catch one.

Suddenly, a shota sharp hiss. A 20-centimeter dart with a red tuft for a tail rockets upward. The shooter is Filipe Abreu, a Ph.D. student at the Oswaldo Cruz Foundation (Fiocruz), a research institute in Rio de Janeiro, Brazil. Abreu looks as if he's been in the wild for weeks: muddy pants, scruffy beard, machete dangling from his belt. He's an entomologist, but the intricate transmission cycle of yellow fever, which involves both monkeys and mosquitoes, compels him to study primates, too.

The shot misses. Instead of leaves, the dart comes clattering down. A second shot also goes awry, striking a branch and bending the needle tip 45.

The party regroups, and Abreu hands the rifle to Marcelo Quintela Gomes, a technician at Fiocruz. The hunters thread through vines and shinny down trees into a gully. Every so often Gomes raises the rifle, then drops it. He eventually takes three shots, all misses. Everyone agrees that the bugios are unusually skittish.

They're not the only ones. Yellow fever has left the people of Brazil feeling edgy as well. Over the past 8 months, they've endured vaccine shortages, lurid media stories, and the occasional slaughter of innocent monkeys. To stem such problems, scientists have scoured this massive country to figure out where the virus lurks and how it's spreadingknowledge vital to fighting future outbreaks as well. But fear remains, especially the fear that yellow fever will ravage the megacities along Brazil's east coastor push even beyond that.

We've seen Zika march up to the United States, says Seth Berkley, CEO of Gavi, the Vaccine Alliance, in Geneva, Switzerland. So have dengue fever, chikungunya, and other mosquito-borne diseases. There's no reason to think yellow fever won't do the same, he says.

YELLOW FEVER WAS ONCE the world's most feared disease. Most victims suffer only fevers and aching joints, but 15% get walloped: Their eyes and skin turn yellow, and they bleed from the mouth and eyes. (The Spanish name for the disease, vomito negro, means black vomit.) No drugs exist to treat it, and half of those who develop the serious form die as the virus destroys their livers.

Native to Africa, yellow fever spread to the Americas with the slave trade. In 1793, then-President George Washington fled Philadelphia, Pennsylvania (then the U.S. capital), during an epidemic that killed 5000. Later outbreaks nearly derailed the construction of the Panama Canal.

A vaccine developed in the 1930s largely eliminated the disease in North America. Africa and South America, meanwhile, continue to suffer. Sub-Saharan Africa accounts for 90% of cases, including a 2016 outbreak centered in Angola with thousands of victims. But in some ways yellow fever in South America is scarier: Because of the low natural immunity there, it kills one-third of those who contract it.

Brazil seems particularly vulnerable. Yellow fever long ago disappeared into the interior, and given the mere handful of cases most years (2014 saw none at all), few people outside endemic areas get vaccines. But in December 2016, victims began appearing in the east for the first time since 1942. The government confirmed 792 cases in 130 cities nationwide, with several hundred more under investigation. More than half occurred in Minas Gerais (population: 21 million), a southeastern state bordering the states of Rio de Janeiro (17 million) and So Paulo (44 million). One victim reportedly died within 40 kilometers of the city of Rio.

State health ministries, which administer vaccines, have ordered 26.3 million emergency doses since December, but some places still ran short. During Carnival in February, a squirrel monkey died of yellow fever in Utinga State Park in Belm in northern Brazil. After panicked stories in the press, people stampeded vaccine clinics, which had to open extra rooms to contain the crowds. After 12,000 inoculations in 5 days, Belm's clinics exhausted their supply.

Although the onset of winter slowed the outbreak, scientists fear a resurgence next year. When and where it might reappear depends on the erratic and often maddening behavior of three animals: mosquitoes, monkeys, and humans.

TWO TRANSMISSION CYCLES of yellow fever exist in South America. In the sylvatic (jungle) cycle, mosquitoes from two generaSabethes and Haemagogusspread the virus mostly between monkeys, with people (usually loggers or miners in remote areas) bitten and infected only incidentally. But the possibility of an urban cycle looms. Here, a different mosquito, the infamous Aedes aegypti, spreads the disease directly from person to person, and cases quickly multiply. All the recent cases in Brazil have been sylvatica slight misnomer because some have occurred inside citiesbut no human-to-human transmission has occurred.

Bruna Sena Nascimento brings the mosquitoes she catches in the forest (top) back to a lab at the Evandro Chagas Institute in Belm, Brazil (bottom), where she identifies the species and checks for signs of the yellow fever virus.

Pinning down which mosquito species carry the virus can yield clues about who is at risk and where. So on a recent June morning, entomologists from the Evandro Chagas Institute in Belm don green jumpsuits and drive north to the jungle. On the way, they swap stories about all the mosquito-borne diseases they've endured. Leathery old Hlio Saraiva has had three strains of dengue.

They park at a dilapidated banana farm and start gathering equipment. Just in case, bring the big knife, someone says. Saraiva grabs a 45-centimeter machete with ENTOMOLOGIA on the scabbard. As they head off, the farm's resident Dalmatian trots up to join the adventure.

After several turns, they stop. Twelve meters above is a platformor rather, four ragged planks. Yellow fever mosquitoes dine on monkeys in the canopy, so researchers have to scale trees, too. There's no ladder, just a few dozen nails pounded into the trunk to hoist yourself up. It's a drenching climb in the heat.

An ignorant reporter asks what they use for mosquito bait. Bruna Sena Nascimento, an animated entomologist, laughs. We are the bait. Oh. Mosquitoes are attracted to the carbon dioxide that primates exhale. So unlike with monkeys, hunting mosquitoes is easy: Just sit and waitand hold off on the bug spray.

In the old days, researchers sometimes sat on platforms in their underwear, counting bites and noting what parts of the body mosquitoes preferred. Now, fully clothed scientists use short white nets to nab mosquitoes in the air. They then slip tubes into the nets, suck the bugs up with their lungs, and puff them out into collection vesselsanything from sawed-off sections of PVC pipe to plastic Teenage Mutant Ninja Turtles cups with lids. (Entomology is a cheap science, Abreu says. You improvise.) A half-day in the canopy can net a few hundred skeeters.

Back at the lab in Belm, Nascimento freezes and sorts her mosquitoes, focusing on the abdominal stripes or sweeping back legs that distinguish various species. After the sorting, the mosquitoes go into vials filled with saline and a BB. An automatic agitator then liquefies the bugs, producing a foamy gray ink with floating legs. The fluid is added to cell cultures to test for yellow fever.

Although scientists know the disease's main vectors in Brazil, they're still investigating whether others play a role. One mystery is how outbreaks shift from sylvatic to urban and what species drive that shift. Perhaps miners or loggers simply carry the virus back to cities. But certain mosquitoes might play a role, too. Abreu suspects that A. albopictus, the Asian tiger mosquito, which often straddles jungle and urban areas, might harbor the virus and could bridge the cycles by introducing cases into new areas.

Even the known vectors wreak plenty of havoc, though. Says Thomas Monath, a yellow fever expert at NewLink Genetics, a biotech company in Ames, Iowa: In Brazil, they've drawn a line that supposedly demarcates risk. We vaccinate people on one side and don't vaccinate people living on the other side. But mosquitoes aren't observing that demarcation.

IF MOSQUITOES ARE THE VILLAINS of yellow fever, monkeys are the main victims. A lack of natural immunity leads to devastating outbreaks for many South American species, especially howler monkeys. In the throes of the disease, Abreu says, they often descend from trees to riverbanks to slake their thirst, but lack the strength to climb up again. They end up shivering in the dirt, wracked with pain.

During the Brazilian outbreak, health officials nationwide asked people to report sightings of sick or dead monkeys so they could test for yellow fever. They received reports of 5300 dead monkeys since the outbreak started, with an unknown number related to yellow fever. Biologists also carried out active vigilance campaigns, such as the hunts on Ilha Grande.

Shooting monkeys on those hunts is only half the challenge. After the tranquilizer hits, scientists have about 5 minutes before the monkey passes out and plummetsduring which time they're scrambling about with a net, hoping like crazy it doesn't wander into some inaccessible area. Once it lands safely, they check its gums, eyes, and genitals for yellow discoloration, then take blood from the groin to test for virus. Although the monkey usually wakes within an hour, it might remain loopy for several more, rendering it vulnerable to falling or a jaguar attack. So scientists usually detain itone group uses a red dog carrieruntil it recovers its wits.

Most people in Brazil know that monkeys can catch yellow fever. Alas, many also believe that monkeys infect people, which isn't true. (Mosquitoes do.) As a result, people in rural areas sometimes shoot monkeys or leave poisoned fruit around, adding dozens of casualties to an already devastating outbreak. Killing monkeys ends up harming humans as well, says Jlio Bicca-Marques, a primatologist at the Pontifical Catholic University of Rio Grande do Sul in Porto Alegre, Brazil: The death of monkeys from yellow fever is the first warning that the virus is circulating. In other words, monkeys are sentinels, he says, early detection systems. Without the monkeys in our forests, we'll be blind.

HUMAN BEINGS, the third actor in this drama, are the least predictable. Miners and loggers, some with fake immunization cards, jet between sylvatic regions and cities in just hours, potentially transferring the virus to new areas. Cutting down forests also exposes people to mosquitoes that would otherwise remain hidden.

Building homes in forest clearings, a common practice in Brazil, is especially risky. On one side of the road might sit shanties with chickens wandering about and satellite dishes anchored onto mossy boulders. On the other, a wall of thick jungle with vibrant red tropical birds and playful monkeys. Jozelene Beckmann, who lives in Belm, home of the state park where the squirrel monkey died, says that monkeys used to cavort along her rooftop and slip inside her home. Unfortunately, where monkeys go, mosquitoes followas does yellow fever. After years of ignoring recommendations, Beckmann finally got vaccinated in mid-June.

Briefly anesthetized, a monkey has its blood drawn to check for yellow fever virus.

Vaccinating infants for yellow fever is already mandatory in northern and Amazonian states, where the disease is endemic, and some scientists propose extending the law nationwide. But because vaccination carries a small riskone in 300,000 people develops full-blown yellow fever after vaccination and another one in 100,000 develops meningitisthe government has stopped short of mandating it for everyone, instead merely recommending it. Many people in Rio and other cities ignore the recommendation. One problem is that most vaccine clinics keep short hours, and with the Brazilian economy struggling, people can't take time off work to visit.

The low compliance frustrates scientists because inoculation could basically eliminate yellow fever nationwide, and do so at a pittance. A single dose given as an infant that costs a dollar is effective for life. That's extraordinary, Monath says. During the Angolan emergency last year, health officials stretched vaccine supplies with fractional doses of one-fifth the normal amount, and even that seemed to offer short-term protection.

Still, making the vaccine has its challenges. It's hard to scale up production, for one thing, partly because many steps are still performed by hand, the same basic way they were in the 1930s. Manufacturers grow the virus in chicken eggs, which workers must candle one by one with hand lamps to check for signs of live embryosveins, eyes, movement. (Dead eggs are discarded.) A single technician might examine 8000 eggs per week. Technicians also must burn holes in the eggshells with torches to introduce the virus, and later burn more holes around the waist of the egg to extract the infected embryos for grinding in blenders. It's not quite artisanal vaccine production, but it's close.

Another problem is more perverse: The vaccine is almost too good at preventing yellow fever. Because it costs so little and protects people for life, making it isn't profitable. Worldwide, just four institutes bother, including Fiocruz. Manufacturers also dislike the uneven market for it: low demand most years, followed by outbreaks that leave them scrambling. Production at Fiocruz, for instance, jumped from 25 million doses in 2016 to a planned 70 million this yearwhich forced the institute to cut back severely on its vaccine for measles, mumps, and rubella.

The market could soon change, however. The World Health Organization (WHO) recently brokered deals in several African and South American countries to vaccinate 584 million people for yellow fever over the next decade, with a goal of eliminating all outbreaks worldwide by 2026. That campaign should steady the market by ensuring stable demand. To boost supply, Fiocruz is also building a new $1 billion plant west of Rio that, in a few years, could produce up to 100 million doses of yellow fever vaccine annually.

Still, WHO notes that production of vaccine almost always lags behind projections. Lack of urgency among political leaders could also weaken the campaign. Public health authorities, says Monath, can basically forget about [the disease] in between these horrible episodes. So although the new Fiocruz facility will help, eliminating outbreaks worldwide remains an ambitious goal. The quick spread of Zika and other mosquito-borne diseases from South America up to Texas and Florida also suggests that yellow fever will be hard to tame.

During the yellow fever outbreak this year, public health clinics in Belm, Brazil, vaccinated hundreds of people daily.

But the danger of yellow fever in North America pales in comparison with the disaster that could arise if it ever spread to Asia. Even though southern Asia has all the prerequisites for yellow fevermonkeys, mosquitoes, a warm climatethe disease has never gained a foothold on the world's most populous continent. Perhaps, some scientists speculate, other diseases there provide cross-immunity. Or perhaps humans have simply been lucky. But last year, 11 Chinese men working in Angola developed yellow fever upon returning home, the first confirmed cases in Asian history. Thankfully, the disease spread no further. But if the urban cycle ever got established there, 1.8 billion peoplevirtually all unvaccinated and presumably with high genetic susceptibilitycould be vulnerable.

Moreover, the struggle to contain yellow fever, a familiar disease with an effective vaccine, does not augur well for our ability to combat the new diseases that will almost certainly emerge as people push deeper into jungles. As Jon Abramson, a pediatrician at Wake Forest University in Winston-Salem, North Carolina, and a yellow fever adviser for WHO, puts it: If we can't stop outbreaks with yellow fever, we're in a lot of trouble with other outbreaks.

IN BRAZIL, the quest to stop the current outbreak continues. On Ilha Grande, after the howler monkeys scatter, the hunting party takes a break to catch insects. Sometimes we get mosquitoes and can't get monkeys; other times, we get monkeys but can't get mosquitoes, Abreu says philosophically. Both are important.

But after tracking those two creatures all morning, Abreu and Gomes now switch their attention to the final animal in the yellow fever triad: humans. To that end, they visit the abandoned prison nearby, now a museum.

Locals there are gossiping about a tourist who recently found a dead monkey nearby and posted a picture on Facebook. Unfortunately, something dragged the carcass off before authorities could test it for yellow fever.

Abreu befriends the museum guard, whose backyard is a popular crossing point for monkeys. She's quite taken with the tranquilizer rifle, and he shows her how it works. Afterward they exchange contact information, so she can alert him if she sees sick or dead monkeys. She then asks Abreu whether it's true that monkeys give yellow fever to humans. He assures her that they don't.

Late the next morning, Gomes finally bags a bugio, a female. Instead of tumbling from the canopy, she slides down a thick shaft of bamboo like that pole the firemen come down, Abreu says. But she is unharmed, and they get a good blood sample.

A few weeks later, the results come back: negative for yellow fever. That's a reliefno sign yet that this ancient scourge has infiltrated the island paradise. But with nearby mainland cities confirming cases and tourists pouring in, it might not be long. As the rest of Brazil has shown, exemption from yellow fever today is no guarantee of a safe tomorrow.

Link:
On the trail of yellow fever - Science Magazine

Read More...

Northern Ireland mum fighting MS: Russian medics are now my last hope – Belfast Telegraph

August 17th, 2017 8:44 pm

Northern Ireland mum fighting MS: Russian medics are now my last hope

BelfastTelegraph.co.uk

A young Co Down mum is bravely undergoing a gruelling stem cell transplant in Russia in what she believes is her last hope of enjoying some quality of life.

http://www.belfasttelegraph.co.uk/news/northern-ireland/northern-ireland-mum-fighting-ms-russian-medics-are-now-my-last-hope-36023340.html

http://www.belfasttelegraph.co.uk/life/features/article36023337.ece/4289a/AUTOCROP/h342/2017-08-12_lif_33652492_I8.JPG

A young Co Down mum is bravely undergoing a gruelling stem cell transplant in Russia in what she believes is her last hope of enjoying some quality of life.

Lindsay Rice (35) from Warrenpoint has exhausted every treatment on the health service - including chemotherapy normally given to cancer patients - in the hope of treating the chronic condition Rapidly Evolving Severe Relapsing Remitting Multiple Sclerosis.

Paralysis and temporary sight loss are just a few of the many debilitating symptoms which have left the mum-of-two unable to enjoy normal family life.

Desperate to get her help, her family launched an appeal on Facebook and Go Fund Me to raise 50,000 to send her to the National Pirogov Medical Surgical Centre in Moscow where she arrived two weeks ago to start her stem cell transplant.

The treatment alone is expected to cost up to 45,000 and, incredibly, in just 12 weeks the family has raised 32,000 towards a 50,000 target thanks to generous support from friends and the public.

Lindsay, who is married to Liam (36), a financial advisor, has two children, Jamie (17) and Olivia (8).

Liam says: "This is her last hope and she is doing it for her family and her kids and that's what she is focusing on. She just wants to be able to live a normal life and do normal things with the family."

Since starting her treatment on August 1 she has been keeping a daily dairy of her progress through a Facebook page - Lindsay's Last Hope.

While the groundbreaking treatment known as HSCT (Haematopoietic Stem Cell Transplant) is not a cure for MS, Lindsay's hope is that it will halt the progression of the disease and stop the frequent and severe relapses which are destroying her health.

Lindsay will spend a month in the clinic, most of it in isolation, and when she comes home she faces a long recovery period when she will have to remain isolated for up to a year due to the risk of infection.

HSCT aims to 'reset' the immune system to stop it attacking the central nervous system. It uses chemotherapy to remove the harmful immune cells and then rebuild the immune system using a type of stem cell found in the patient's bone marrow.

The haematopoietic stem cells used in the treatment can produce all the different cells in the blood, including immune cells. However, they can't regenerate permanently damaged nerves or other parts of the brain and spinal cord.

Lindsay has successfully had over two million stem cells extracted in a tough procedure which involved having a catheter inserted into her jugular vein. She has also had her head shaved this week in preparation for starting chemotherapy today.

The chemotherapy will wipe out her immune system and she will then have her stem cells transplanted back into her blood by a drip to help regrow a new, stronger immune system.

She will then have to spend 10 days in complete isolation while her new immune system builds.

Also, since arriving in Russia she has been told that her MS is now much worse than she realised and is now at the Secondary Progressive stage.

People with Secondary Progressive MS don't tend to recover completely from a relapse and can expect a general worsening of symptoms, making the treatment even more time-critical.

In a further blow, tests have picked up a potentially dangerous three-centimetre active lesion on her spine which wasn't spotted during MRI's here.

Lindsay faces a tough few weeks in her bid to halt the progression of the disease but as her husband Liam explains, the alternative is the prospect of life in a wheelchair: "Lindsay has come through a lot since her teens.

"She had Jamie quite young at 18 and her condition seemed to really deteriorate after that. She went to a lot of consultants and had many tests but it wasn't until after she had Olivia that she was finally diagnosed in 2011.

"She never knows from day to day how it will affect her. Fatigue is the number one problem and that is crippling. I would come home from work and after dinner she has to go to bed, and even sleep doesn't help it.

"It stops her from doing simple things like taking our daughter to the park or taking the dog for a walk.

"Her motability is not as good as an average person and the other big issue is the relapses.

"They have become very frequent and each relapse is worse in terms of how severe it is. During her last one in February she had to go into hospital and also had to use a walking frame.

"A common misconception is that after each relapse you go back to normal but that's not the case. It leaves its mark and any damage done is permanent. The nature of the relapses could leave her in a wheelchair."

It was after her last relapse and having exhausted all options for treatment on the Health Service that Lindsay decided she wanted to try HSCT.

Her neurologist in Belfast supported her decision and the family applied to the Russian clinic just 12 weeks ago expecting to wait up to two years before admission.

They were surprised to be offered a cancellation on August 1 leaving them facing a race against time to raise 50,000 to cover the cost of treatment and expenses.

Liam says: "We thought we would have at least 12 months and up to two years to get the money together and it has been amazing to see how people have rallied round and what they have done just from the kindness of their hearts, especially strangers.

"We've had quizzes and coffee mornings and online auctions and I recently did the Four Peaks challenge with a group of friends. Lindsay's mum and her best friend are organising a lot of events and we still have some way to go but we are amazed at how much has been raised and donated in such a short time."

Liam flew to Russia with Lindsay on July 31 and stayed with her for five days while she underwent tests to determine that she was suitable for the treatment.

It has already been a punishing two weeks for Lindsay who has come through a batch of invasive procedures including having a catheter inserted in her jugular to extract the stem cells.

Liam says: "It is an intense treatment and Lindsay is so positive and coping brilliantly. She got her hair cut short before she went and decided to have it shaved this week before the chemo starts and it falls out.

"She will have to spend 10 days in complete isolation to allow her immune system to build again and that will be tough.

"She will hopefully be home after 30 days and then when she comes home she will have a long recovery and will have to isolate herself from society for up to a year to keep her safe from infection.

"We will have to deep clean the house and we will all have to wear face masks as she can't risk even getting a cold."

Liam is back at work and trying to keep things as normal as possible at home for the couple's two children, who he said are coping well: "Jamie is 17 and approaching adulthood and understands why she is doing it and is okay, but obviously his mum is away and he has his sixth year exam results coming and he misses her.

"Olivia seems to be fine too. She understands her mum has MS, which stops her doing things with her and she knows this treatment is to help her to be a better mother.

"I've been trying as much as possible to keep her occupied with play dates and sleepovers."

The couple have been impressed by the level of care in the clinic and Lindsay has had the chance to meet and get to know other MS patients from all over the world.

Liam has nothing but admiration for her strength and the positive way she is enduring the extreme procedures she faces.

He adds: "Lindsay is the most determined person you could ever possibly meet. She has had bad days and it can be demoralising for her but she is determined to be as positive as she can be.

"It is not a cure. MS doesn't have a cure but we hope it will stop the progress of the disease. We just hope it will halt it by rebooting her immune system and hopefully stop the severe relapses."

Liam adds: "It is desperately hard and stressful for all of us and we have to put a positive spin, in the grand scheme of things it is just for a month of her life."

Follow Lindsay's journey at Facebook/Lindsay's Last Hope - HSCT in Russia

Fundraising continues as the family has only until the end of the month to reach their target. You can support this young mum in her bid to enjoy a normal quality of life by going to https://www.gofundme.com/lindsay-slasthope

Belfast Telegraph

View original post here:
Northern Ireland mum fighting MS: Russian medics are now my last hope - Belfast Telegraph

Read More...

Former basketball star Greg Friel in fight of his life – Sports – fosters … – Foster’s Daily Democrat

August 17th, 2017 8:44 pm

Mike Whaley mwhaley@fosters.com @mwhaley25

Greg Friel can deal with the pain, as bad as it can be. Its the uncertainty about his future well-being that makes life difficult.

A former basketball star at Oyster River High School and Dartmouth College, Greg, 38, was diagnosed with relapsing remitting multiple sclerosis in 2010.

This unpredictable, often disabling disease of the central nervous system has weakened his body, particularly his legs below the knees, to the point where he often has to get around with a cane, and sometimes a walker.

Im in constant pain, he said. Its terrible. But Ive got a beautiful wife. Ive got a business where Im my own boss. Its a challenge. If you know the Friels, were up for a challenge. But its scary.

Fortunately, for Greg, there might be a light at the end of the tunnel. Next month, he will fly to Russia with his Uncle Bob for hematopoietic stem cell transplantation (HSCT). After being on the waiting list for three-plus years, Greg was recently granted admission to the treatment program.

The catch is that the cost for travel and treatment will be around $100,000. The treatment is not covered by insurance, so Gregs wife, Anastagia, has set up a GoFundMe page to raise funds to pay for the trip and treatment (https://www.gofundme.com/gregfrielhsct). As of Saturday morning, nearly $53,000 has been raised in three weeks.

Greg flies to Moscow on Sept. 24 for the month-long treatment, which begins on Sept. 26 at Piragov Hospital.

MS is so unpredictable, Anastagia said. Its hard to see my husband, a pillar of strength in the family, going through a weak time.

Hes such a positive person, she added. Hes charismatic. Theres such a light around him. Its hard to deny his charisma, and hes charming.

The treatment includes chemotherapy, where Greg said they shock your system down to zero. Good stem cells are injected, so basically its a stem cell rebirth.

It wasnt easy for Greg to reach out for help. An independent financial advisor in Boston, he was used to being the one helping out. It was in his nature to give.

My wife, my mom and my siblings told me I needed to open myself up, said Greg, who stands 6-foot-5. It was difficult. But if you get it early, you get proactive and you get things done, you can be in fine shape.

Thats the high-road approach Greg is taking.

Thats the athletic mentality, he said. Youre competitive because you care.

nnn

Greg comes from primo competitive stock. His dad, the late Gerry Friel, was the head mens basketball coach at the University of New Hampshire for 20 seasons (1969-89).

Greg is the middle child of five siblings. All of them played basketball at Oyster River and all five scored over 1,000 career points (Keith tallied over 2,000 points). They also all played Division I college basketball: Jennifer (UNH), Keith (Notre Dame, Virginia), Greg (Dartmouth), Jeremy (UNH) and Jilliane (UNH).

Greg and Keith starred at Oyster River in the mid-1990s, leading the Bobcats to back-to-back Class I championships in 1995 and 96.

Keith speaks fondly of those years playing with his brother. Greg was always two steps ahead and always competing. He did the little things, all the extra stuff that others didnt want to do. He loved to win, even if that meant diving for a ball or taking charges.

Greg was Wojo before Wojo, Keith said, referencing the feisty former Duke University guard of the late 1990s, Steve Wojciechowski. He was always firing up the other team, getting in their heads.

Plus he had that deadly 3-point stroke.

Greg graduated in 1997, attended New Hampton School for a post-graduate year where he counted future NBA star Darius Songaila (whos still a close friend) and Pistol Pete Maravichs son, Jason, among his teammates. Greg started for New Hampton and led them to the New England Class A prep championship game where they lost to Maine Central Institute.

Originally committed to the University of North Carolina at Wilmington, Greg decided to accept an offer from Dartmouth, coached by Somersworth native Dave Faucher, a former assistant at UNH under Gregs dad.

Two of Fauchers sons played at Lebanon High School, whom Oyster River beat in the 1995 Class I championship, 55-52. Greg set a tournament championship record with five 3-pointers in that game, a record he still shares 22 years later with two other players.

UNC-Wilmington would not let him out of his commitment, so he had to sit out a year before joining the Dartmouth team in the fall of 1999.

Greg played four years for the Big Green, serving as a captain as a senior. He graduated with a degree in economics and a minor in sociology.

As a player he got the chance to compete against both his brothers, although Jeremy laughs, I was on the bench while he was playing. I didnt get in.

Greg has been a financial advisor for 14 years, the last nine as his own man, running his own business.

He met his future wife while judging a beauty pageant in Las Vegas in 2009. A successful model, Anastagia has been Miss Teen Florida USA, Miss Florida USA and Miss Bahama Universe. She has also appeared in Sports Illustrateds swimsuit issue.

She actually didnt want to be at that particular pageant in 2009, but went at her moms behest and finished second.

They communicated on Facebook and it blossomed from there. Greg and Anastagia were married in May of 2014.

nnn

In 2010, when Greg was diagnosed with MS, it started with headaches.

I was feeling weak, he said. I was working 80-90 hours a week, so I was thinking it could have been that. I just kept getting weaker and weaker, my legs mostly. I was feeling lethargic. I didnt have any energy.

His legs hurt. He described it as a charley horse: You cant move, he said. Youre stuck in mud. It felt like youre cutting (to the basket) and someone knees your leg muscle. Thats what it felt like all the time.

At its worse, Greg said he couldnt move, couldnt walk, couldnt get out of bed.

Greg took a very aggressive drug called Tysabri for 4 years that cost $22,000 a month for an infusion and was partially covered by insurance. But it wasnt a cure and he didnt know the long-term effects. That was a concern since he and Anastagia want to have children.

Now theres hope with the Russian treatment.

Gregs cousin, Brendan Friel, who suffered from the same MS, went to Russia for treatment and is back in good health.

He just had his three-year stem cell anniversary, Greg said. And now hes working full-time.

Anastagia said they did their research. (The treatment) is invasive, but its got a good track record, she said.

What Greg finds irritating is that the procedure is covered by insurance for cancer, ALS and rheumatoid arthritis, but not MS.

Its crazy, he said.

As expected, its been difficult for his family.

Its heart-wrenching, said Joan, his mom. Its been more debilitating in the past year than ever. Hes going downhill since Thanksgiving of last year. Its one little setback after another this time. He has to do something; otherwise it will get so much worse.

Joan said shes there as a mom. Thats my job and I embrace it for all my children. Im a sounding board.

She added, I dont need to be intrusive. Im there if they need me and want me and, sometimes, if they dont.

Greg maintains an upbeat attitude.

Im good, he said. I try to stay positive. Ive always been a pretty positive person mentally.

nnn

The Friels have been touched by the outpouring of donations in such a short time, some from old adversaries or teammates Greg hasnt seen in 20 years.

Its not like one person wrote a check for $20,000, Greg said. Over 300 people have donated. Its very humbling. Its nice to see the support.

Later this month there will be a fundraiser at The Warehouse Bar & Grille, 40 Broad Street, in Boston to raise funds for Gregs treatment. It is being put together by a couple of old basketball opponents, Cliff Dever (Timberlane) and Marshall Chrane (Bishop Brady).

Chrane was on the Brady team that Gregs OR team beat in the 1996 Class I final, 58-49. Chrane returned the favor in 1997, hitting two foul shots with no time on the clock to beat Oyster River by a point in the tournament quarterfinals, Gregs last high school game.

The fundraiser will take place from 1 to 4 p.m. on Aug. 27.

There will be raffles, which include, among others, items donated by former pro and college football coach, Chip Kelly; UNH hockey coach Dick Umile and UMass-Amherst athletic director Ryan Bamford, Gregs old AAU teammate.

The journey to get Greg his treatment is certainly gaining momentum.

Were determined to get this right, he said.

Anastagia agrees.

I dont want anyone to be fighting alone, she said. Were committed to fighting this thing together.

Which is what good teammates do.

More:
Former basketball star Greg Friel in fight of his life - Sports - fosters ... - Foster's Daily Democrat

Read More...

Europe Mesenchymal Stem Cells Market Forecast 2022 Study covering Strategies, Application, Growth Estimation and … – satPRnews (press release)

August 17th, 2017 8:44 pm

A new research document with title Europe Mesenchymal Stem Cells Market by Manufacturers, Countries, Type and Application, Forecast to 2022 covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like Germany, UK, France, Russia, Italy and important players/vendors such as Thermo Fisher, Bio-Techne, ATCC, etc The report will help user gain market insights, future trends and growth prospects for forecast period of 2017-2022

Request a sample report @ https://www.htfmarketreport.com/sample-report/643003-europe-mesenchymal-stem-cells-marketMesenchymal Stem Cells (MSC), also termed Mesenchymal Stromal Cells, are multipotent cells that can differentiate into a variety of cell types and have the capacity for self-renewal.

Scope of the Report:

This report focuses on the Mesenchymal Stem Cells in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and application.

Market Segment by Manufacturers, this report covers

Lonza

Thermo Fisher

Bio-Techne

ATCC

MilliporeSigma

PromoCell GmbH

Genlantis

Celprogen

Cell Applications

Cyagen Biosciences

Axol Bioscience

Market Segment by Countries, covering

Germany

UK

France

Russia

Italy

Market Segment by Type, covers

Human MSC

Mouse MSC

Rat MSC

Other

Market Segment by Applications, can be divided into

Research Institute

Hospital

Others

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/643003-europe-mesenchymal-stem-cells-market

There are 17 Chapters to deeply display the Europe Mesenchymal Stem Cells market.

Chapter 1, to describe Mesenchymal Stem Cells Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Mesenchymal Stem Cells, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers in Europe, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the Europe market by countries, covering Germany, UK, France, Italy and Russia, with sales, price, revenue and market share of Mesenchymal Stem Cells, for each country, from 2012 to 2017;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type and application, from 2012 to 2017;

Chapter 7, 8, 9, 10 and 11, to analyze the key countries by manufacturers, Type and Application, covering Germany, UK, France, Italy and Russia, with sales, revenue and market share by manufacturers, types and applications;

Chapter 12, Mesenchymal Stem Cells market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2017 to 2022;

Chapter 13, to analyze the manufacturing cost, key raw materials and manufacturing process etc.

Chapter 14, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 15, to describe Mesenchymal Stem Cells sales channel, distributors, traders, dealers etc.

Chapter 16 and 17, to describe Mesenchymal Stem Cells Research Findings and Conclusion, Appendix, methodology and data source

.Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/643003-europe-mesenchymal-stem-cells-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=643003Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@htfmarketreport.comPh: +1 (206) 317 1218

Go here to see the original:
Europe Mesenchymal Stem Cells Market Forecast 2022 Study covering Strategies, Application, Growth Estimation and ... - satPRnews (press release)

Read More...

Achromatopsia: Gene Therapy Cures Eye Disease? – NBC 5 Dallas-Fort Worth

August 17th, 2017 3:45 am

Imagine only being able to see the things in front of you in soft focus, and just in black and white. For people with the genetic eye condition achromatopsia those are just some of the side effects. But, researchers are testing a new treatment designed to cure the condition by fixing the gene responsible.

Each time Tara Cataldo prepares to leave her house, she has to make sure her face is completely shielded from the sun.

I need to have very dark, very tinted sunglasses to feel comfortable outside and to see really well. Cataldo said.

Cataldo has achromatopsia, a genetic condition that makes her eyes incredibly sensitive to light. She is also very nearsighted; even while wearing glasses or contacts, she can only see clearly at a very short distance.

I cannot drive a car so I rely on public transportation and my bike to get around. Cataldo explained.

"There are currently no approved and no effective treatments for achromatopsia, said University of Florida surgical ophthalmologist Christine Kay.

Kay is working to change that. She is one of a handful of experts testing a gene therapy.

For achromatopsia the cells we have to target are cone cells responsible for decreased vision and color vision and those are cells at the very bottom layer of the retina, Kay explained.

Using a tiny cannula, surgeons deliver a normal copy of one of two mutated genes; the CNGA3 or CNGB3 gene, directly into the eye - restoring vision.

Cataldos myopia is so severe that her risk of retinal detachment from any retinal surgery is high, which rules her out for the current trial. In the meantime, Cataldo says shes learned to adapt to achromatopsia and live without limitations.

And I hope all young achromats learn the same thing, Cataldo said.

Kay says if the gene could eventually be delivered to the surface of the retina; additional patients, like Cataldo, could be treated. Applied Genetic Technologies Corporation, the biotech company that developed the therapies, and several U.S. universities have successfully tested this therapy in dogs and sheep.

Published at 2:10 PM CDT on Aug 16, 2017

Read the original here:
Achromatopsia: Gene Therapy Cures Eye Disease? - NBC 5 Dallas-Fort Worth

Read More...

Global Cancer Gene Therapy Market to Grow at a CAGR of 20.6% by 2021: Favorable Government Regulations for … – Markets Insider

August 17th, 2017 3:45 am

DUBLIN, August 16, 2017 /PRNewswire/ --

The "Global Cancer Gene Therapy Market 2017-2021" report has been added to Research and Markets' offering.

The global cancer gene therapy market to grow at a CAGR of 20.63% during the period 2017-2021.

The report, Global Cancer Gene Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is favorable government regulations for gene therapy programs. Gene therapy has been a big hope for the individuals suffering from rare diseases and various forms of cancers. Cancer is one of the biggest life-threatening diseases across the globe and has been a huge point of concern for the healthcare providers. This has led to rising support to R&D activities in cancer gene therapy from various governments.

According to the report, one driver in the market is rising geriatric population. The global geriatric population is continues to grow at a faster pace due to several factors such as rapidly falling fertility rates and growing life expectancy due to better medical facilities. The US Census Bureau reported that the total population aging 65 years and above was estimated at 617 million in 2015 and is expected to rise to 1,566 million by 2050. Asia has the largest and fastest growing aging population due to several factors such as the huge population of the region, government policies such as one child policy of China has reduced the addition of young population, and higher investment in the healthcare sector has led to better medical facilities and longer life expectancy.

Further, the report states that one challenge in the market is high cost of gene therapy treatment. The sky-high cost of gene therapy has made it a point of debate across the globe. One of the major causes for the exorbitant cost of gene therapy is the requirement of intensive clinical trials. The gene therapy needs to be tailored to suit the genetic acceptance for each individual, unlike small and large molecule drug clinical trials where the trials are done in large and random samples. In the clinical trials of gene therapy, the stem cell is extracted from each patient's bone marrow, then the correct version of the gene is mingled with the cell, and the corrected stem cells are introduced to the individual patient.

Key vendors

Other prominent vendors

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Segmentation By Therapy

Part 07: Geographical Segmentation

Part 08: Decision Framework

Part 09: Drivers And Challenges

Part 10: Market Trends

Part 11: Vendor Landscape

Part 12: Key Vendor Analysis

Part 13: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/drvk7v/global_cancer

Media Contact:

Research and Markets Laura Wood, Senior Manager rel="nofollow">press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Link:
Global Cancer Gene Therapy Market to Grow at a CAGR of 20.6% by 2021: Favorable Government Regulations for ... - Markets Insider

Read More...

Cancer Gene Therapy Market – Forecasts and Opportunity Assessment by Technavio – Business Wire (press release)

August 17th, 2017 3:45 am

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global cancer gene therapy market is expected to grow at a CAGR of almost 21% during the forecast period.

This research report titled Global Cancer Gene Therapy Market 2017-2021 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The rising prevalence rate of cancer has been a huge challenge for the global economies as the disease leads to high rate of mortality and economic losses. The current treatment options available come with many drawbacks such as severe side effects and relapse of cancer. These factors have led to high investment in the R&D for development of various novel therapies with cancer gene therapy being one of the major ones of them. The therapy mainly uses three types of treatment options namely oncolytic virotherapy, gene transfer therapy, and gene-induced immunotherapy.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavios healthcare and life sciences research analysts categorize the global cancer gene therapy market into the following segments by therapy. They are:

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Oncolytic virotherapy

Oncolytic virotherapy is one of the fastest growing treatment modality. In this therapy, the anti-cancer cells specifically destroy the cancer cells without causing harm to the normal cells. Each virus has a specific cellular tropism that determines which tissue will be preferentially infected by the virus and thus will further lead to the disease.

According to Sapna Jha, a lead oncology research analyst from Technavio, The oncolytic virotherapy has shown encouraging results in the pre-clinical studies. The novel treatment option holds great opportunity to make a significant effect on quality and length of the life of the individual. Adenovirus is the most commonly used virus in oncolytic virotherapy.

Gene transfer

Gene transfer or gene insertion is one of the most exciting and emerging cancer treatment methods. The therapy is expected to be the fastest growing type of therapy in the cancer gene therapy market. This is a radical new treatment method that involves the introduction of a new gene into the cancer cell or the surrounding tissues.

Genes with different functions have been proposed for this therapy; some of them include antiangiogenesis genes, cellular stasis genes, and suicide genes. Many different viral vectors are used to deliver these genes, Adenovirus being most common of them. Other than viral vectors, certain non-viral methods are also studied in the various clinical trial, which includes oligodendromer DNA coatings and naked DNA transfer, adds Sapna.

Gene-induced immunotherapy

Immunotherapy works on the concept of boosting the immune system of the individual to target and destroy cancer cells. However, traditional immunotherapy has shown limited success rate in the field. Various gene therapy techniques are being used to overcome this limitation.

The next-generation gene-induced immunotherapy vaccines are already in clinical trial. Gene-induced immunotherapy is a type of gene therapy where genetically engineered genes are used to generate an immune response against cancer. Growing knowledge and understanding of mechanisms regulating the initiation and maintenance of cytotoxic immune response has led to the designing of several genetic immunization strategies.

The top vendors highlighted by Technavios research analysts in this report are:

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View post:
Cancer Gene Therapy Market - Forecasts and Opportunity Assessment by Technavio - Business Wire (press release)

Read More...

Global Research Antibodies Market 2017-2022 – Increasing Demand for Personalized Medicine and Protein … – PR Newswire (press release)

August 17th, 2017 3:45 am

The global research antibodies market (including reagents) is projected to reach USD 12.60 Billion by 2022 from USD 9.33 Billion in 2017, growing at a CAGR of 6.2% during the forecast period.

Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and growing collaboration between industries and academic institutes are the key drivers of the market.

The report analyzes the global research antibodies market (including reagents) by product, technology, application, end user, and region. Based on product, the market is segmented into reagents and antibodies. The reagents segment accounted for the major share of the research antibodies market (including reagents) in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.

Furthermore, based on type, the reagents market has been further segmented into media & sera, stains & dyes, fixatives, buffers, probes, solvents, enzymes, and others (controls, stabilizers, and diluents). The media & sera segment is expected to dominate the market in 2016 due to its high usage in all types of assays, culture procedures, and techniques.

Market Dynamics

Key Market Drivers

Key Market Opportunities

Key Challenges

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Research Antibodies Market, By Product

7 Research Antibodies Market, By Technology

8 Research Antibodies Market, By Application

9 Research Antibodies Market, By End User

10 Research Antibodies Market, By Region

11 Competitive Landscape

12 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/xgmch2/research

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-research-antibodies-market-2017-2022---increasing-demand-for-personalized-medicine-and-protein-therapeutics-300505197.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read this article:
Global Research Antibodies Market 2017-2022 - Increasing Demand for Personalized Medicine and Protein ... - PR Newswire (press release)

Read More...

NIH gives nod to Vibrent Health for precision medicine work – Healthcare IT News

August 17th, 2017 3:45 am

Vibrent Health's cloud-based precision medicine platform has gained authority to operate from the National Institutes of Health, a certification that it meets federal privacy and security standards and paving the way for the company's work on the landmark research cohort that will fuel the Precision Medicine Initiative

"This ATO certification marks a significant milestone for Vibrent in its journey to power the next generation of personalized medicine," said the company's CEO Praduman Jain, in a statement.

Vibrent's SaaS platform combines genomic information with data from electronic health records, medical devices, wearables and more.

[Also:NIH All of Us program gearing up for 'precision engagement,' Eric Dishman says]

It will be the technology around which the All of Us Research Program will be based as the precision medicine project works to enroll more than one million participants in its cohort to understand how genomics, lifestyle, behavioral, and environmental factors impact an individuals health.

In addition to NIH, Vibrent's technology is at use at Johns Hopkins, Stanford, the U.S. Veterans Administration, UnitedHealth Group and Medtronic.

For the ATO certification, the company worked with Coalfire, a third-party assessment organization, to develop security plans, policies, procedures, scanning, SSP, and pen testing, per FISMA risk management framework, to ensure the integrity of its platform, officials said. Coalfire confirmed that Vibrent Health has the necessary operational and technical controls in place to provide a secure environment for federal systems, bureaus, departments, and their supporting entities.

Twitter:@MikeMiliardHITNEmail the writer: mike.miliard@himssmedia.com

Like Healthcare IT News on Facebook and LinkedIn

Read more from the original source:
NIH gives nod to Vibrent Health for precision medicine work - Healthcare IT News

Read More...

Computing cancer – Pamplin Media Group

August 17th, 2017 3:45 am

Technology could speed the process of precision medicine; Beaverton firm is at forefront.

Ganapati "Gans" Srinivasa is not a doctor, but he just might hold the key to saving millions of lives.

Srinivasa is famous for being the chief architect of the Xeon processor, a 400 MHz Pentium microprocessor from Intel for use in mid-range enterprise servers and workstations. The device is found in most modern technological devices.

Srinivasa is chief executive officer of Omics Data Automation, a resident company at the Oregon Technology Business Center and one of five winners of the 2017 Beaverton Challenge winners. The company is designing and selling software in the precision medicine area to aggregate data for cancer treatment centers and hospitals.

"We can talk about gadgets, but so what? This is the Holy Grail," Srinivasa said of his current project to assist medical professionals working with cancer patients who are faced with a mountain of data from a wide and confusing array of sources.

And he's not alone in that opinion.

"A patient with a newly diagnosed cancer may undergo many different types of tests, but the results of these tests exist in separate data silos," said Dr. Chris Corless, director of the Knight Diagnostic Laboratories, Oregon Health & Science University. A data silo is a separate database or set ofdatafiles that are not part of an organization's enterprise-widedataadministration.

"Omics will aggregate and analyze the very large quantity of data contained across all of these silos, which will result in faster diagnostics and more effective treatments," Corless said.

According to Srinivasa, there are currently about 16 million cancer survivors in the United States and, of those, about 600,000 are expected to die from some form of cancer, making it the second deadliest disease next to heart disease.

Precision medicine is a lot more than stethoscopes and X-ray machines."It's an eye-opener how dependent precision medicine is on computation,"? saidMichael Wrimm, Ph.D, a principal with Omics.

The treatment of cancer isn't justa "race with time," it's also an expensive effort, Srinivasa said. His goal is to provide this service in a price range of $100 to $500 per patient to compute and store information for 10 years.

Omics recently was awarded a grant from the National Science Foundation for $224,903 to develop technology that will help patients receive faster and more accurate diagnosis and treatment. This capability has the potential to help patients with cancer and other serious medical conditions. Omics also recently received a $500,000 contract with the University of California, Los Angeles Hospital.

The vision of Omics Data Automation in the Oregon Technology Business Center Incubator, is for effective precision medicine treatment each patient has be characterized, analyzed and targeted with a plan tailored to inhibit their cancer. Precision treatment is an informatics enterprise that aims to expedite and perfect the process so the most precise, tailored treatment plan can be generated in one day using all the information available.

Srinivasa said the specialized computation of treatment for cancer and what Omics is doing is a timesaver and a lifesaver. Omics has grown from about four principals at the beginning of the year to 11 contributors to the project now.

Wrimm said precision medicine seems exotic, but the company tries to make it accessible to all.

Omics develops infrastructure for aggregating multidimensional data to enable customers to build and scale up clinical practices while keeping the costs low, so lifesaving technology is available for everyone.

Omics is designing and selling software in the precision medicine area to aggregate data for cancer treatment centers and hospitals.

Wrimm and Srinivasa said they both left their "cushy Intel jobs" to make a difference in the world.

Omics looks for groups of population cohorts that have a similar set of variations.

Steve Morris, executive director of the Oregon Technology Business Center, said, "I think this project really has exciting potential this whole idea of personalized medicine takes you (the patient) into account right down to the genome. It's a great example of incubation. Gans (Srinivasa) is awesome in terms of technology and this has excellent potential to make a very big splash worldwide."

The broader impact/commercial potential of this small business innovation project is that patient medical information comes in many diverse forms including genomic sequences, medical images and clinical observations.

The integration of the various data sources across patient populations have shown to reveal patterns and similarities among patients, which inform treatment options. With advances in imaging and genomic sequencing technologies, the sheer volume of available information is growing exponentially, straining current computational approaches and creating an imminent need for scalable data integration, Srinivasa said.

The ability to overcome the data mountain opens the door to support precision medicine and provide enhanced services to medical institutions. With Omics innovations, patients can receive faster and more accurate diagnoses and treatments, clinicians can deliver verified treatment decisions through patient cohort comparison, hospitals have better standard of care and society overall will potentially be empowered by supporting global treatment options and well-informed pharmaceutical development, Srinivasa added.

The project develops a scalable aggregation, a technique for improving the interactive behavior of database systems, and analysis of factors and circumstances that cause a patient's symptoms to improve or worsen. The project blends all that information to help create personalized diagnosis and therapy for each patient.

But bringing all that information together in one place for the doctors to find is the trick.

The project aggregates features from genomics (the branch of molecular biology concerned with the structure, function, evolution and mapping of genomes), imaging and clinical characterization of patients. This enables identification of groups of patients based on both genotypes (the genetic constitution of an individual organism) and phenotypes (the set of observable characteristics of an individual resulting from the interaction of its genotype with the environment).

For more information, visit omicsautomation.com.

Continued here:
Computing cancer - Pamplin Media Group

Read More...

OECS highlights outstanding Grenadian making strides in biotechnology – St. Lucia News Online

August 17th, 2017 3:44 am

Dr. Dwayne E. Carter,Post Doctoral Researcher, Tissue Applications.

(PRESS RELEASE) A national of Grenada, Dr. Dwayne E. Carter received his formation in the sciences at the Grenada Boys Secondary School and the T. A. Marryshow Community College in his hometown of Saint Georges.

Dwayne would later migrate to the United States to further pursue his passion for medicine and his curiosity to better understand and cure diseases that plague the human race. After years of study, Dwayne completed his doctoral training in cell biology at the University of Texas Medical Branch where he primarily focused on acute alcohol induced liver injury.

In 2016, he joined ORGANOVO Holdings Inc. as a post-doctoral researcher in liver tissue bioengineering with a focus on modeling progressive liver diseases. Throughout his graduate training, Dwayne received numerous awards for meritorious research from national scientific meetings and has two publications in peer reviewed journals.

When asked about the advice that he would give to young persons in the sub region that may be interested in an investigative science career, Dwayne said: This is a long road but the journey is worth it. A tip is to always make goals for yourself and plan strategic ways to achieve those goals.

Also be prepared to fight for what you want! Very few things are handed to you in this world, so brace yourself for times of adversity because you will inevitably be faced with challenges and the way you deal with them determines your success or failure.

At this stage in my life I consider myself a fighter, I look forward to the challenges because Ive learnt that they bring forward my best, he said.

Dr. Carter will be delivering a presentation on Modeling Human Biology, Drug Response and Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue at the Committee Lecture Hall at TSRI, La Jolla, California at 7:00pm today, August 16, 2017.

ABOUT THE PRESENTATION:

Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterised by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognised as the most common cause of chronic liver disease, with a prevalence of 25% worldwide, and is projected to become the leading indication for liver transplant by 2025.

Despite decades of research in rodents and 2D cell cultures, the mechanisms of NAFLD progression, therapeutic approaches and non-invasive diagnostics are still resoundingly absent. Thus, there is a significant need for a more predictive human multicellular 3D in vitro model to study the progression of steatosis into NASH.

Using immune competent ExVive Human Liver Tissue, an in vitro 3D bioprinted liver, Dr. Carter will show preliminary data where the key features of NASH such as steatosis, fibrosis and inflammation will be modeled via nutrient overload followed by inflammatory stimulation using prototypical inducers.

ABOUT THE OECS FEATURE SERIES:

The OECS Feature Series is an initiative that seeks to feature the accomplishments of consummate professionals from OECS Member States making strides within the region and in the Diaspora.

The project highlights one outstanding OECS national per month and aims to inspire the regions youth to think big and open their minds to extraordinary possibilities through the success stories of their OECS peers.

Criteria for nominations include: being a national of an OECS Member State; possessing an academic distinction of the highest order; scientific invention; high political accomplishment (regionally and in the Diaspora); and extraordinary community or national service achieved (regionally and in the Diaspora).

This article was posted in its entirety as received by stlucianewsonline.com.This media house does not correct any spelling or grammatical error within press releases and commentaries.The views expressed therein are not necessarily those of stlucianewsonline.com, its sponsors or advertisers.

See the rest here:
OECS highlights outstanding Grenadian making strides in biotechnology - St. Lucia News Online

Read More...

Page 938«..1020..937938939940..950960..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick